Palivizumab(pa live ah zoo’ mab)
Synagis
PREGNANCY CATEGORY C
Drug Classes
Antiviral
Monoclonal antibody
Therapeutic Actions
A murine and human monoclonal antibody produced by recombinant DNA technology specific to an antigenic site of the RSV; has neutralizing effects on the RSV.
Indications
Prevention of serious lower respiratory tract disease caused by RSV in pediatric patients at high risk for RSV disease
Contraindications and Cautions
Contraindicated with allergy to palivizumab or any murine product.
Use cautiously with fever (antipyretics should be used to decrease fever before beginning therapy); previous administration of palivizumab (antibodies frequently develop, causing a risk of serious reactions on repeat administration); pregnancy, history of bleeding disorders.
Available Forms
Injection—50 mg/0.5 mL, 100 mg/mL
Dosages
Administer IM only.
Pediatric patients 24 mo and younger
15 mg/kg IM as a single injection, once a month during RSV season, with first dose given before start of RSV season. Give injection preferably in anterolateral aspect of thigh; do not use gluteal muscle because of risk of damaging sciatic nerve. For cardiopulmonary
bypass patients, administer a dose as soon as possible following procedure, even if less than 1 month since previous dose.
bypass patients, administer a dose as soon as possible following procedure, even if less than 1 month since previous dose.
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
